Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

A case of occult bowel perforation after a cycle of chemotherapy for advanced epithelial ovarian carcinoma.

Zhou X, Hu P, Yue Y, Duan Z.

Eur J Gynaecol Oncol. 2012;33(5):540-2.

PMID:
23185808
2.
3.

Neoadjuvant chemotherapy followed by interval cytoreductive surgery in patients with unresectable, advanced stage epithelial ovarian cancer: a single centre experience.

Bilici A, Salepci T, Dane F, Gumus M, Ustaalioglu BB, Seker M, Salman T, Turan C, Unal O, Yaylaci M.

Arch Gynecol Obstet. 2010 Oct;282(4):417-25. doi: 10.1007/s00404-009-1330-7.

PMID:
20035339
4.

Quantification of free plasma DNA before and after chemotherapy in patients with advanced epithelial ovarian cancer.

Capizzi E, Gabusi E, Grigioni AD, De Iaco P, Rosati M, Zamagni C, Fiorentino M.

Diagn Mol Pathol. 2008 Mar;17(1):34-8. doi: 10.1097/PDM.0b013e3181359e1f.

PMID:
18303408
5.

[Potential value of CA125 kinetic monitoring in the initial management of advanced epithelial ovarian cancer].

Vignot S, Brochet C, Debord C, Lauratet B, Bernard M.

Ann Biol Clin (Paris). 2011 Sep-Oct;69(5):597-604. doi: 10.1684/abc.2011.0620. French.

6.
7.

Serum HE4 Profile During Primary Chemotherapy of Epithelial Ovarian Cancer.

Hynninen J, Auranen A, Dean K, Lavonius M, Carpen O, Perheentupa A, Seppänen M, Grénman S.

Int J Gynecol Cancer. 2011 Dec;21(9):1573-8. doi: 10.1097/IGC.0b013e3182225509.

PMID:
21811175
8.

Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab?

Richardson DL, Backes FJ, Hurt JD, Seamon LG, Copeland LJ, Fowler JM, Cohn DE, O'Malley DM.

Gynecol Oncol. 2010 Jul;118(1):47-51. doi: 10.1016/j.ygyno.2010.01.011.

PMID:
20382413
9.

Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer.

Pölcher M, Eckhardt M, Coch C, Wolfgarten M, Kübler K, Hartmann G, Kuhn W, Rudlowski C.

Cancer Chemother Pharmacol. 2010 May;66(1):203-7. doi: 10.1007/s00280-010-1276-2.

PMID:
20204367
10.

Does severe anemia caused by dose-dense paclitaxel-Carboplatin combination therapy have an effect on the survival of patients with epithelial ovarian cancer? Retrospective analysis of the Japanese gynecologic oncology group 3016 trial.

Kumagai S, Sugiyama T, Shoji T, Michimae H, Katsumata N, Aoki D, Terauchi F, Jobo T, Ochiai K, Yasuda M.

Int J Gynecol Cancer. 2011 Dec;21(9):1585-91. doi: 10.1097/IGC.0b013e318229266a.

PMID:
22123713
11.

The prognostic value of CA-125 in epithelial ovarian cancer patients during and after chemotherapy.

Lukácskó I, Hernádi Z, Sápy T, Borsos A.

Acta Chir Hung. 1997;36(1-4):213-4.

PMID:
9408350
12.

Interaction between preoperative CA-125 level and survival benefit of neoadjuvant chemotherapy in advanced epithelial ovarian cancer.

Kang S, Kim TJ, Seo SS, Kim BG, Bae DS, Park SY.

Gynecol Oncol. 2011 Jan;120(1):18-22. doi: 10.1016/j.ygyno.2010.09.024.

PMID:
21035174
13.

Intraperitoneal chemotherapy for recurrent epithelial ovarian cancer is feasible with high completion rates, low complications, and acceptable patient outcomes.

Skaznik-Wikiel ME, Lesnock JL, McBee WC, Beriwal S, Zorn KK, Richard SD, Krivak TC, Edwards RP.

Int J Gynecol Cancer. 2012 Feb;22(2):232-7. doi: 10.1097/IGC.0b013e318234f833.

PMID:
22080886
14.

The impact of pretreatment thrombocytosis and persistent thrombocytosis after adjuvant chemotherapy in patients with advanced epithelial ovarian cancer.

Lee M, Kim SW, Nam EJ, Yim GW, Kim S, Kim YT.

Gynecol Oncol. 2011 Aug;122(2):238-41. doi: 10.1016/j.ygyno.2011.04.012.

PMID:
21531448
15.

The predictive and prognostic value of serum CA 125 half-life during paclitaxel/platinum-based chemotherapy in patients with advanced ovarian carcinoma.

Gadducci A, Cosio S, Fanucchi A, Negri S, Cristofani R, Genazzani AR.

Gynecol Oncol. 2004 Apr;93(1):131-6.

PMID:
15047226
16.

Evaluation of whether serum tumor markers in patients with epithelial ovarian carcinoma change following chemotherapy.

Li XP, Xu QY, Wang JL, Wang SJ, Zhao Y, Wei LH.

Chin Med J (Engl). 2012 Feb;125(3):410-5.

17.
18.

Serum TRAIL levels in patients with epithelial ovarian cancer or primary peritoneal cancer treated with neoadjuvant chemotherapy. A pilot study.

Gasowska-Bodnar A, Bodnar L, Synowiec A, Jerzak M, Wcislo G, Smoter M, Szczylik C, Baranowski W.

Eur J Gynaecol Oncol. 2011;32(6):642-6.

PMID:
22335026
19.

Intravenous/intraperitoneal paclitaxel and intraperitoneal carboplatin in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma: a feasibility study.

Nagao S, Iwasa N, Kurosaki A, Nishikawa T, Ohishi R, Hasegawa K, Goto T, Fujiwara K.

Int J Gynecol Cancer. 2012 Jan;22(1):70-5. doi: 10.1097/IGC.0b013e318234f927.

PMID:
22146766
20.

[Combination chemotherapy with nedaplatin and paclitaxel for ovarian cancer].

Yamamoto T, Morishige K, Ohta Y, Kamiura S, Saji F.

Nihon Rinsho. 2004 Oct;62 Suppl 10:550-3. Japanese. No abstract available.

PMID:
15535306
Items per page

Supplemental Content

Support Center